Home

Atlas Venture Associates Opportunity I, L.P.

CIK 1780065 · last filed 2024-02-09

Atlas Venture Associates Opportunity I, L.P. is a corporate insider who has filed 3 SEC Form 4 insider transactions across 2 companies since 2019. The most recent filing shows the insider sold $3.8K of XLO on Feb 9, 2024. Across all open-market trades the lifetime net is +$25.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.8M across reported positions. The firm reports its address in Cambridge, MA. 43 SEC filings were submitted jointly with Atlas Venture Associates Opportunity I, LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.77M

Companies

2

Total Filings

3

Lifetime Open-Market Net

$25.89M

Filer Profile

Reported Address
400 TECHNOLOGY SQUARE
10TH FLOOR
CAMBRIDGE, MA 02139
Phone
(857) 201-2700
State of Incorporation
DE
Related Filers
Atlas Venture Associates Opportunity I, LLC — 43 joint filings, latest 2026-02-09
Atlas Venture Opportunity Fund I, L.P. — 42 joint filings, latest 2026-02-09
ATLAS VENTURE ASSOCIATES X, L.P. — 21 joint filings, latest 2026-02-09
Atlas Venture Associates X, LLC — 21 joint filings, latest 2026-02-09
Atlas Venture Fund X, L.P. — 19 joint filings, latest 2026-02-09
Atlas Venture Fund XI, L.P. — 18 joint filings, latest 2024-02-28
Atlas Venture Associates XI, L.P. — 17 joint filings, latest 2024-02-28
Atlas Venture Associates XI, LLC — 17 joint filings, latest 2024-02-28
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
XLO 10%+ Owner 196,722 $9.00 $1.77M -$25.4K 2 2024-02-09
Akero Therapeutics, Inc. (AKRO) Delisted 10%+ Owner 505,099 $54.65 $27.60M $25.92M 1 2019-06-25

Recent Filings

3 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-02-09 XLO Sell (S) −6,000 -$3.8K EDGAR
2024-01-16 XLO Sell (S) −25,410 -$21.6K EDGAR
2019-06-25 Akero Therapeutics, Inc. (AKRO) Delisted Mixed +23,849,148 $25.92M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.